Valneva SE (VALN) EBT (2021 - 2026)
Valneva SE's (VALN) quarterly EBT came in at -$36.6 million in Q1 2026, down 348.31% year-on-year from $14.7 million in Q1 2025, and up 38.47% quarter-over-quarter from -$59.5 million in Q4 2025.
Valneva SE (VALN) EBT (2021 - 2026) Analysis & Trends
Valneva SE has disclosed EBT across 6 years of filings, most recently posting -$36.6 million for Q1 2026.
- EBT for Q1 2026 came in at -$36.6 million, down 348.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$160.2 million (down 90.79% YoY), and the FY2025 annual result was -$132.8 million, down 982.29% from the prior year.
- EBT came in at -$36.6 million for Q1 2026 at Valneva SE, up from -$59.5 million in the prior quarter.
- In the past five years, EBT ranged from a high of $72.9 million in Q3 2022 to a low of -$153.3 million in Q2 2022.
- The 5-year median for EBT is -$28.7 million (2022), against an average of -$26.2 million.
- Across the five-year window, EBT soared 426.81% in 2024 and plunged 348.31% in 2026, its largest moves.
- Valneva SE's EBT stood at -$48.9 million in 2022, then jumped by 37.8% to -$30.4 million in 2023, then decreased by 13.7% to -$34.6 million in 2024, then tumbled by 72.01% to -$59.5 million in 2025, then surged by 38.47% to -$36.6 million in 2026.
- The last three EBT figures came in at -$36.6 million (Q1 2026), -$59.5 million (Q4 2025), and -$50.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -36.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.58 Mn |
| Dec 31, 2025 | -59.46 Mn |
| Sep 30, 2025 | -50.82 Mn |
| Jun 30, 2025 | -13.37 Mn |
| Mar 31, 2025 | -8.16 Mn |
| Dec 31, 2024 | -34.57 Mn |
| Sep 30, 2024 | -14.23 Mn |
| Jun 30, 2024 | -27.03 Mn |
| Mar 31, 2024 | 64.01 Mn |
| Dec 31, 2023 | -30.40 Mn |
| Sep 30, 2023 | -34.35 Mn |
| Jun 30, 2023 | -22.41 Mn |
| Mar 31, 2023 | -19.59 Mn |
| Dec 31, 2022 | -48.87 Mn |
| Sep 30, 2022 | 72.91 Mn |
| Jun 30, 2022 | -153.32 Mn |
| Mar 31, 2022 | -28.66 Mn |
| Dec 31, 2021 | 199.40 Mn |
| Sep 30, 2021 | -186.98 Mn |
| Jun 30, 2021 | -69.44 Mn |